Drug-Induced QT Interval Prolongation: Mechanisms, Risk Factors, Genetics and Clinical Management
Drug-Induced QT Interval Prolongation: Mechanisms, Risk Factors, Genetics and Clinical Management
Long QT syndrome (LQTS) characterized by prolongation of the QT interval, may occur as congenital or drug-induced forms. Drug-induced QTinterval prolongation (DI-QTP) is closely associated with severe ventricular arrhythmias [especially torsade de pointes (TdP)] and sudden cardiacdeath. In particular, development of DI-QTP is generally associated with multiple risk factors. Cardiac and non-cardiac drugs may cause QTinterval prolongation (QTP) and TdP. Most of the QT-prolonging drugs act by blocking the rapid component of the delayed rectifier potassiumchannel whereas a smaller number of drugs act by modifying Ca2+ and Na+ currents. In addition, pharmacokinetic drug interactions areamong the reasons of DI-QTP. The corrected QT interval (QTc) according to heart rate by Bazett’s formula is the most commonly used. Geneticsusceptibility is another important issue in predicting DI-QTP and TdP risk. Silent mutations and/or polymorphisms associated with cardiacion channels may cause a risk for DI-QTP. Firstly, for treatment, drugs that cause QTP should be stopped rapidly, electrolyte abnormalities andother pathologies should be rapidly corrected. Intravenous magnesium sulphate, overdrive pacing, isoproterenol and plasma alkalinisationvia sodium bicarbonate are the main useful treatments for DI-QTP and related TdP therapy. Class 1B antiarrhythmic drugs and intravenouspotassium are thought to may be effective in TdP.The purpose of this article is to review the underlying mechanisms of QTP, risk factors and genetics of DI-QTP, how to measurement of QTinterval and treatment of acquired LQTS.
___
- 1. Van Noord C, Eijgelsheim M, Stricker BH. Drug- and non-drugassociated QT interval prolongation. Br J Clin Pharmacol 2010;70:16–
23. [CrossRef]
- 2. Testai L, Cecchetti V, Sabatini S, Martelli A, Breschi MC, Calderone V.
Effects of KATP openers on the QT prolongation induced by HERGblocking drugs in guinea-pigs. J Pharm Pharmacol 2010;62:924–930.
[CrossRef]
- 3. Beitland S, Platou ES, Sunde K. Drug-induced long QT syndrome and
fatal arrhythmias in the intensive care unit. Acta Anaesthesiol Scand
2014;58:266–272. [CrossRef]
- 4. Cubeddu L. Drug-induced Inhibition and Trafficking Disruption of
ion Channels: Pathogenesis of QT Abnormalities and Drug-induced
Fatal Arrhythmias. Curr Cardiol Rev 2016;12:141–154. [CrossRef]
- 5. Tisdale JE. Drug-induced QT interval prolongation and torsades de
pointes: Role of the pharmacist in risk assessment, prevention and
management. Can Pharm J (Ott) 2016;149:139–152. [CrossRef]
- 6. Uvelin A, Pejaković J, Mijatović V. Acquired prolongation of QT
interval as a risk factor for torsade de pointes ventricular tachycardia:
a narrative review for the anesthesiologist and intensivist. J Anesth
2017;31:413–423. [CrossRef]
- 7. Thomas SHL, Behr ER. Pharmacological treatment of acquired
QT prolongation and torsades de pointes. Br J Clin Pharmacol
2016;81:420–427. [CrossRef]
- 8. Isbister GK. Risk assessment of drug-induced QT prolongation. Aust
Prescr 2015;38:20–24. [CrossRef]
- 9. Trinkley KE, Page RL 2nd, Lien H, Yamanouye K, Tisdale JE. QT interval
prolongation and the risk of torsades de pointes: essentials for
clinicians. Curr Med Res Opin 2013;29:1719–1726. [CrossRef]
- 10. Konstantopoulou A, Tsikrikas S, Asvestas D, Korantzopoulos P, Letsas
KP. Mechanisms of drug-induced proarrhythmia in clinical practice.
World J Cardiol 2013;5:175–185. [CrossRef]
- 11. Li G, Cheng G, Wu J, Zhou X, Liu P, Sun C. Drug-induced long QT
syndrome in women. Adv Ther 2013;30:793–802. [CrossRef]
- 12. Kallergis EM, Goudis CA, Simantirakis EN, Kochiadakis GE, Vardas
PE. Mechanisms, risk factors, and management of acquired long QT
syndrome: a comprehensive review. Sci World J 2012;2012:212178.
[CrossRef]
- 13. Nachimuthu S, Assar MD, Schussler JM. Drug-induced QT interval
prolongation: mechanisms and clinical management. Ther Adv Drug
Saf 2012;3:241–253. [CrossRef]
- 14. Lazzara R. Amiodarone and torsade de pointes. Ann Intern Med
1989;111:549–551. [CrossRef] https://doi.org/10.7326/0003-4819-
111-7-549
- 15. Letsas KP, Efremidis M, Filippatos GS, Sideris AM. Drug-induced long
QT syndrome. Hellenic J Cardiol 2007;48:296–299. Available at: https://
www.hellenicjcardiol.org/archive/full_text/2007/5/2007_5_296.pdf
- 16. Yap YG, Camm AJ. Drug induced QT prolongation and torsades de
pointes. Heart 2003;89:1363–1372. [CrossRef]
- 17. Isbister GK, Page CB. Drug induced QT prolongation: the
measurement and assessment of the QT interval in clinical practice.
Br J Clin Pharmacol 2013;76:48–57. [CrossRef]
- 18. Barra S, Agarwal S, Begley D, Providência R. Post-acute management
of the acquired long QT syndrome. Postgrad Med J 2014;90:348–358.
[CrossRef]
- 19. Beach SR, Celano CM, Noseworthy PA, Januzzi JL, Huffman JC. QTc
prolongation, torsades de pointes, and psychotropic medications.
Psychosomatics 2013;54:1–13. [CrossRef]
- 20. Kannankeril PJ, Roden DM. Drug-induced long QT and torsade de
pointes: recent advances. Curr Opin Cardiol 2007;22:39–43. [CrossRef]
- 21. Roden DM. Drug-induced prolongation of the QT interval. N Engl J
Med 2004;350:1013–1022. [CrossRef]
- 22. Kannankeril P, Roden DM, Darbar D. Drug-induced long QT
syndrome. Pharmacol Rev 2010;62:760–781. [CrossRef]
- 23. Antzelevitch C. Role of transmural dispersion of repolarization in
the genesis of drug-induced torsades de pointes. Heart Rhythm
2005;2:S9–S15. [CrossRef]
- 24. Smits JP, Blom MT, Wilde AA, Tan HL. Cardiac sodium channels and
inherited electrophysiologic disorders: a pharmacogenetic overview.
Expert Opin Pharmacother 2008;9:537–549. [CrossRef]
- 25. Gupta A, Lawrence AT, Krishnan K, Kavinsky CJ, Trohman RG. Current
concepts in the mechanisms and management of drug-induced QT
prolongation and torsade de pointes. Am Heart J 2007;153:891–899.
[CrossRef]
- 26. Drew BJ, Ackerman MJ, Funk M, et al. Prevention of torsade de pointes
in hospital settings: a scientific statement from the American Heart
Association and the American College of Cardiology Foundation. J
Am Coll Cardiol 2010;55:934–947. [CrossRef]
- 27. Schwartz PJ, Woosley RL. Predicting the Unpredictable: DrugInduced QT Prolongation and Torsades de Pointes. J Am Coll Cardiol
2016;67:1639–1650. [CrossRef]
- 28. Tamargo J. Drug-induced torsade de pointes: from molecular biology
to bedside. Jpn J Pharmacol 2000;83:1–19. [CrossRef]
- 29. Varró A, Baczkó I. Cardiac ventricular repolarization reserve: a
principle for understanding drug-related proarrhythmic risk. Br J
Pharmacol 2011;164:14–36. [CrossRef]
- 30. Spellmann I, Reinhard MA, Veverka D, et al. QTc prolongation in
short-term treatment of schizophrenia patients: effects of different
antipsychotics and genetic factors. Eur Arch Psychiatry Clin Neurosci
2018;268:383–390. [CrossRef]
- 31. Nakano Y, Shimizu W. Genetics of long-QT syndrome. J Hum Genet
2016;61:51–55. [CrossRef]
- 32. Shimizu W. Clinical impact of genetic studies in lethal inherited
cardiac arrhythmias. Circ J 2008;72:1926–1936. [CrossRef]
- 33. Yang P, Kanki H, Drolet B, et al. Allelic variants in long-QT disease
genes in patients with drug-associated torsades de pointes.
Circulation 2002;105:1943–1948. [CrossRef]
- 34. Sesti F, Abbott GW, Wei J, et al. A common polymorphism associated
with antibiotic-induced cardiac arrhythmia. Proc Natl Acad Sci U S A
2000;97:10613–10618. [CrossRef]
- 35. Abbott GW, Sesti F, Splawski I, et al. MiRP1 forms I Kr potassium
channels with HERG and is associated with cardiac arrhythmia. Cell
1999;97:175–187. [CrossRef]
- 36. Schwartz PJ, Spazzolini C, Crotti L, et al. The Jervell and Lange-Nielsen
syndrome: natural history, molecular basis, and clinical outcome.
Circulation 2006;113:783–790. [CrossRef]
- 37. Eftekharian A, Mahani MH. Jervell and Lange-Nielsen syndrome in
cochlear implanted patients: our experience and a review of literature.
Int J Pediatr Otorhinolaryngol 2015;79:1544–1547. [CrossRef]
- 38. Tranebjaerg L, Bathen J, Tyson J, Bitner-Glindzicz M. Jervell and
Lange-Nielsen syndrome: a Norwegian perspective. Am J Med Genet
1999;89:137–146. [CrossRef]
- 39. Roston TM, Cunningham T, Lehman A, Laksman ZW, Krahn AD,
Sanatani S. Beyond the Electrocardiogram: Mutations in Cardiac
Ion Channel Genes Underlie Nonarrhythmic Phenotypes. Clin Med
Insights Cardiol 2017;11:1179546817698134. [CrossRef]
- 40. Pfeufer A, Sanna S, Arking DE, et al. Common variants at ten loci
modulate the QT interval duration in the QTSCD Study. Nat Genet
2009;41:407–414. [CrossRef]
- 41. Newton-Cheh C, Eijgelsheim M, Rice KM, et al. Common variants
at ten loci influence QT interval duration in the QTGEN Study. Nat
Genet 2009;41:399–406. [CrossRef]
- 42. Bektaşoğlu G, Yılmaz M, Turgut O, Tandoğan İ. Uzun QT sendromları.
Cumhuriyet Med J 2009;31:487–501. Available at: https://dergipark.
org.tr/tr/download/article-file/47583
- 43. Khan IA. Long QT syndrome: diagnosis and management. Am Heart J
2002;143:7–14. [CrossRef]
- 44. Khan IA, Gowda RM. Novel therapeutics for treatment of long-QT
syndrome and torsade de pointes. Int J Cardiol 2004;95:1–6. [CrossRef]